Rubius Therapeutics Company
Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics.
Technology:
Atrificial Vectors and Immune Cells, Cell-based gene therapy
Industry:
Atrificial Vectors and Immune Cells, Public
Headquarters:
Cambridge, Massachusetts, United States
Founded Date:
2013-01-01
Employees Number:
101-250
Funding Status:
IPO
Investors Number:
1
Total Funding:
445000000
Estimated Revenue:
$10M to $50M
Last Funding Date:
2021-03-16
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership